Introducing REYOBIQ™: The FDA-Accepted Proprietary Name for Plus Therapeutics’ Lead Drug Candidate
Big News from Plus Therapeutics! The U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name REYOBIQ™ (rhenium Re186 obisbemeda) for our lead therapeutic candidate.
🔬 What is REYOBIQ™?
REYOBIQ™ is a targeted radiotherapeutic designed to address brain tumors and metastatic cancers, offering precision treatment with the potential to improve patient outcomes. This milestone marks a significant step in advancing our mission to develop innovative cancer therapies.
Learn More:
📢 Press Release: Read more
🔬 About REYOBIQ™: Discover the science
Stay connected for updates as we continue to develop next-generation radiotherapeutics.
#BrainCancer #BrainTumor #Glioblastoma #MetastaticCancer #Oncology #CancerResearch #ClinicalTrials #FDA #Radiotherapeutics
Recent Comments